Theseus Pharmaceuticals, which aimed to overcome the resistance that cancers develop to drugs, is laying off most of its staff and exploring options that could lead to deals that eke out some value ...

As a snot-nosed child, Greek mythological tales always held a certain kind of irresistible fascination for me. Whether it was the adventures of Jason and the Argonauts, or the endlessly impressive ...

Theseus is an intriguing prospect in the Tyrosine Kinase Inhibitor drug development space. Its management team contains several members of the team at Ariad Pharmaceuticals - acquired by Takeda in a ...

Theseus Pharmaceuticals is being acquired by Concentra Biosciences at a cash price of $4.05 per share. Shareholders will also receive a contingent value right that includes 80% of the net proceeds ...

Virtual reality has only been available at retail for about a year, so it’s understandable that we’re still seeing a lot of experimentation and innovation in this space. First-person games are the ...